Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The safety profile shows minimal adverse events, with injection site irritation occurring in less than 3% of female participants across multiple clinical trials
Investigational Peptides in Soft Tissue Healing. World Anti-Doping Agency (WADA) Guidelines
NAD+ elevation: Downstream increase in cellular NAD+ and SIRT1 activity observed alongside NNMT inhibition
Common Protocol: CJC-1295: 100200 mcg 12x daily, subcutaneous Ipamorelin: 100200 mcg 12x daily, subcutaneous (often injected together with CJC-1295) Cycle: 812 weeks, can be run longer depending on goals 4
Compounds like this are of research interest but are not proven therapies
10.1097/ICO.0b013e31821dd986 143 TurkovicB.SikiricP.SeiwerthS.MiseS.AnicT.PetekM.et al (2004)
US$ 21.18
US$ 21.40
US$ 24.60
US$ 27.98
US$ 27.03
